Beam Therapeutics (BEAM) - The company is developing a pipeline using base editing technology, which modifies single DNA or RNA bases without cutting the DNA strand [1] - Beam Therapeutics ended Q2 with 1billionincash,providinganoperatingrunwayinto2027[1]−Thecompanyrecentlyreceivednewdrugclearanceforitsfirstin−vivoregulatoryfiling,enablinggeneticmodificationsviananoparticlesinjectedintothebody[2]−InitialclinicaldataforBEAM−302inAlpha−1AntitrypsinDeficiency(AATD)isexpectedin2025,withthefirstpatientdosedinphase1and2trials[3]−NewplayersinthebiotechspacecouldlicenseBeam′sbase−editingtechnology,potentiallybenefitingthecompanyanditsshares[3]BloomEnergy(BE)−BloomEnergysignedanagreementwithAmericanElectricPower(AEP)inNovembertoprovidepowersolutionstodatacenters[4]−Thestockhaspulledbacktoits505 billion valuation and technical support levels [4] - A potential upward movement in the stock could occur in 2025, supported by technical indicators [4] - Bloom Energy is considered a contrarian target with relative strength leadership and significant skepticism among investors [5] - Short interest in BE has reached all-time highs, increasing by 16% in the last 30 days and 48% in 2024, with 23% of the equity's total available float sold short, indicating potential for a short squeeze [5]